Close

Roth Capital Boosts Price Target on TG Therapeutics (TGTX) to $25 on Prelim. TG-1101 Phase 1 Data

July 22, 2014 6:27 AM EDT Send to a Friend
Roth Capital raises its price target on TG Therapeutics (Nasdaq: TGTX) from $20 up to $25 and affirms its Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login